Study for AZD4360 in Participants With Advanced Solid Tumours

Eligibility Criteria

• 1. Participant must be ≥ 18 at the time of signing the ICF.
• 2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
• 3. Minimum life expectancy of 12 weeks in the opinion of the Investigator.
• 5. Contraceptive use by men or women should be consistent with local regulations, as defined by protocol.
• 6. Histologically confirmed advanced or metastatic Pancreatic ductal adenocarcinoma (PDAC), Gastric or Gastroesophageal junction cancer (G/GEJC), and Biliary tract cancer (BTC) with documented positive CLDN18.2 expression.
• 7. Participants must have received at least one prior line of systemic therapy in the advanced/metastatic disease.
• 8. At least one measurable lesion according to RECIST v1.1.
• 1. Human Epidermal Growth Factor Receptor 2 (HER2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G/GEJC participants.
• 2. Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
• 3. Participants with clinically significant ascites that require drainage.
• 4. Central nervous system (CNS) metastases or CNS pathology, as defined by protocol.
• 5. With spinal cord compression or with high risk of paralysis.
• 6. History of non-infectious interstitial lung disease/pneumonitis.
• 7. Participant has cardiac abnormalities, as defined by protocol.
• 8. History of another primary malignancy within 2 years prior to screening.
• 9. Known serologic status reflecting active hepatitis B or hepatitis C.
• 10. Known HIV infection that is not well controlled.
• 11. Active tuberculosis infection.